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ABSTRACT 
 
OBJECTIVES: Hereditary Breast and Ovarian Cancer (HBOC) is an autosomal dominant 
cancer predisposition syndrome with a 46-87% lifetime risk of breast cancer.  Unaffected 
women who have HBOC are eligible for more screening procedures and prophylactic 
surgeries that may reduce the risk of developing cancer by up to 95%. The objectives of 
this study were to assess women’s awareness of and interest in breast cancer genetic 
testing services, as well as women’s attitudes and beliefs regarding the clinical utilization 
of HBOC genetic testing across demographic categories. METHODS: Two-hundred and 
sixty-eight women completed a 35-item survey designed to capture perceptions of HBOC 
and genetic testing, attitudes towards genetic testing for HBOC, and demographics. 
RESULTS: Two-hundred and eight women met participation criteria. One-hundred and 
fifty-five (75%) indicated prior awareness of genetic testing services. One-hundred and 
forty-three (69%) indicated interest in genetic testing for HBOC. Black women, women 
with lower levels of education, and women with lower household incomes reported less 
awareness, but similar levels of interest in genetic testing services when compared to 
other participants.  CONCLUSIONS: Women are interested in genetic testing for HBOC. 
Specific counseling on barriers to minority and low socioeconomic communities, such as 
cost and education regarding genetic testing procedures, may be beneficial in increasing 
utilization of genetic testing for HBOC in these communities. Women who experience 
more discrimination may have increased perceptions of their susceptibility to hereditary 
cancer syndromes and may benefit from personalized risk counseling.
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CHAPTER I. BACKGROUND 
Hereditary breast and ovarian cancer (HBOC) is an autosomal dominant cancer 
predisposition syndrome caused by germline mutations in the breast cancer 1 (BRCA1) 
and breast cancer 2 (BRCA2) tumor suppressor genes.  Individuals who have a pathogenic 
gene mutation in BRCA1 or BRCA2 have a 46-87% life time risk of developing breast 
cancer, compared to a general population risk of 12% (National Comprehensive Cancer 
Network, 2016). A prophylactic bilateral mastectomy in mutation carriers has been found 
to reduce the risk of breast cancer by at least 90% (Hartmann et al., 1999). An estimated 
5-10% of all breast cancer cases are attributable to an inherited mutation (National 
Cancer Institute, 2015). 
 
1.1 Hereditary Breast Cancer 
Breast cancer is a cancer that develops from breast tissue. In the general population, 
one in eight women will develop breast cancer at some point in their lives, making it the 
second most common cancer in women (National Cancer Institute, 2014).  The incidence 
of breast cancer has risen over the past 30 years, most frequently affecting white and 
black women (National Cancer Institute, 2013). Despite the high prevalence of diagnoses 
of breast cancer in white women, they are statistically the least likely to die once 
diagnosed with breast cancer (National Cancer Institute, 2013).  Black women are more 
likely to be diagnosed at a later stage of breast cancer, and to die due to breast cancer 
(Siegal, 2015). Besides ethnicity, Some of the risk factors for developing breast cancer  
	 2 
include older age, higher breast density, a history of radiation therapy, a family or 
personal history of breast cancer, and genetic changes that predispose individuals to the 
development of breast cancer (National Cancer Institute, 2015). 
Five to ten percent of all breast cancer cases are classified as ‘hereditary’, 
meaning that they are caused by an inherited genetic mutation that raises the risk of 
cancer development by ceasing or altering the function of cancer-preventing proteins 
(National Cancer Institute, 2016). The two most common genetic causes of breast cancer 
are the BRCA1 and BRCA2 genes, which are implicated in 20-25% of hereditary breast 
cancer cases (Pharoah et al., 2002). The prevalence of BRCA carriers in the general 
population is estimated to be 1 in 200-400. However, this estimate is based on data from 
breast cancer patient populations and may not reflect the true carrier frequency in the 
general population (Metcalfe et al., 2015).   
When functioning properly, the BRCA genes work to produce proteins that repair 
damage to DNA and regulate transcription. When there are mutations in a BRCA gene, it 
results in the formation of a truncated protein that is unable to regulate cell growth, 
leading to tumorigenesis (Welcsh & King, 2001). Mutations in the BRCA genes are 
associated with an estimated 46-87% lifetime risk of developing breast cancer, markedly 
higher than the 12% risk an average woman has of developing breast cancer (National 
Comprehensive Cancer Network, 2016). Currently, researchers have identified a network 
of over nine genes, including BRCA1 and BRCA2, that are each implicated in raising the 
risk of developing breast cancer to at greater than 20% (National Comprehensive Cancer 
Network, 2016).  
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The vast majority of genetic changes implicated in hereditary breast cancer are 
inherited in an autosomal dominant pattern, meaning only one mutated copy of the two 
genes is required to cause a person to have an increased risk of cancer.  However, 
tumorigenesis only occurs when both copies of the gene are pathogenically mutated. This 
happens naturally, or somatically, as a person ages either through errors in DNA 
replication or through environmental exposures such as tobacco smoke or UV light.  In 
persons with no inherited change, both genes will have been somatically mutated 
throughout their life to cause cancer development. In persons with an inherited mutation 
in a cancer-susceptibility gene, only one detrimental environmental event that 
pathogenically harms the DNA of the un-mutated copy of the gene permanently is needed 
to cause the onset of tumorigenesis, a phenomenon termed the ‘Knudson Two-Hit 
Hypothesis’ (Anderson, 1992). Consequently, patients with an inherited mutation in a 
cancer-susceptibility gene tend to develop cancer at a younger age and at a greater 
frequency than those with no inherited mutation (Burke et al., 1997).  
 
1.2 Hereditary Breast Cancer Screening 
Women who are determined to have a high risk of developing breast cancer, 
either through a known genetic mutation or an extensive family history, are eligible for 
and encouraged to seek high-risk screening procedures to decrease this risk (National 
Comprehensive Cancer Network, 2016). These procedures involve earlier and more 
frequent utilization of physical examinations and imaging techniques (National 
Comprehensive Cancer Network, 2016). These screening techniques have been shown to 
detect a larger number of cases of breast cancer at an earlier stage of the disease 
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(DeSantis et al., 2013; Berg et al., 2012). Women who are considered to have a high risk 
of developing breast cancer may also elect to have risk reducing procedures such as a 
prophylactic mastectomy, which has been shown to reduce the risk of breast cancer by as 
much as 90-95% (Rebbeck et al., 2004). Compared to other cancers, breast cancer has a 
low mortality rate, as approximately 89.7% of women who develop breast cancer will 
still be alive five years after their initial diagnosis (National Cancer Institute, 2014).   
 
1.3 Genetic Testing for Hereditary Breast Cancer 
The BRCA1 gene was first sequenced in 1994 in a collaborative effort by Myriad, a 
genetic researching company, the University of Utah, the National Institute of Health, 
and McGill University (Williams-Jones, 2002).  Shortly after, Myriad filed for 
‘composition-of-matter’ and ‘methods-of-use’ patents on the BRCA1 gene, preventing 
other genetic researching institutions from sequencing the BRCA1 gene for commercial 
use (Williams-Jones, 2002). The sequencing of BRCA2 quickly followed and once again, 
Myriad was among the first to file a U.S. patent on the gene (Williams-Jones, 2002). 
Subsequently, Myriad gained control over the commerical market for genetic testing for 
all of the known hereditary breast cancer genes at the time.  
 The first commercial genetic test for hereditary breast cancer was BRACAnalysis, 
produced and marketed by Myriad in 1996 (Williams-Jones, 2002). Myriad used their 
control on the BRCA testing market to merge their testing service into multiple facets of 
health care and cancer research, partnering with various health insurance companies and 
institutions to allow the test to be covered by health insurance providers and accessible 
for research, at a price (Williams-Jones, 2002). 
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There was initial backlash against the commercialization of BRCA sequencing, 
with the opposition fearing that the test was less focused on the prevention of breast 
cancer and more focused on increasing patient anxiety and the creation of demand for the 
product (Williams-Jones, 2002). Furthermore, Myriad’s patent on BRCA testing created 
barriers to clinical care and delays in research, leading to less effective and efficient 
testing at increased cost, ultimately creating wider health disparity gaps (Offit et al., 
2013). Myriad’s patent was eventually overturned by the Supreme Court in 2013, 
opening the commercial market for hereditary cancer testing and promoting greater 
accessibility to these tests. 
Genetic testing for a hereditary breast cancer mutation can be beneficial to the 
patient in multiple ways.  If a patient has already been diagnosed with breast cancer, 
genetic testing can help inform her treatment. A positive result for a mutation in a cancer 
susceptibility gene may encourage her to opt for a double-mastectomy to reduce her 
likelihood of developing a secondary cancer, as opposed to a cancer-removing 
lumpectomy, which would leave behind more breast tissue and increase the risk of 
recurrence (Wevers, 2014).  In any patient with a family history of breast cancer, 
personally affected or not, knowledge of whether or not there is a hereditary mutation in 
the family can alter reproductive planning and help inform other family members if they 
are at risk as well (Donnelly et al., 2013).  Unaffected patients who test positive for a 
mutation that increases their risk of developing breast cancer are eligible to begin 
following high-risk screening regimens to promote early detection of cancer if it does 
develop, and may begin to consider risk-reducing surgeries, like prophylactic 
mastectomies, to decrease their chance of ever having cancer (Scheuer et al., 2002). 
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Receiving genetic testing, whether the result is positive or negative, has been shown to 
increase utilization of mammography and breast self-exams after result disclosure 
(Botkin et al., 2003). Furthermore, women who know they have a mutation in the BRCA2 
gene are eligible to begin taking Tamoxifen, a chemoprevention drug that reduces the risk 
of breast cancer in women with BRCA2 mutations by approximately 62% (King et al., 
2001).  
  1.3.1 Patient Preferences  
The impact of receiving a positive result for a BRCA mutation has been shown to 
have variable psychological impacts. Studies have suggested that a positive genetic 
testing result for a hereditary cancer syndrome initially leads to an increase in both 
general and cancer-specific anxiety for women with BRCA1 or BRCA2 mutations, but 
that this distress tends to subside significantly with time (Beran et al., 2008; Wilder-
Smith et al., 2007). Women who report more intense emotional representations of 
hereditary cancer and difficulty understanding hereditary cancer are more likely to 
experience distress regarding hereditary cancer testing (Voorwinden & Jaspers, 2015).  
Women cite many reasons as potential influences to sway them from pursing 
genetic testing. Fear of discrimination or stigmatization by employers and health 
insurance companies by use of genetic information has historically been an influence on 
the decision to pursue genetic testing (Apse et al., 2004; Durfy et al., 1999). Women who 
perceive themselves to have a lower risk of developing cancer are less likely to accept an 
offer of genetic testing (Culver et al., 2001).  
Women’s decisions to undergo genetic testing for a hereditary cancer syndrome 
are complicated, with many factors influencing their reasoning for whether or not they 
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should pursue testing. Women who have children or a mother with a cancer history are 
more likely to choose to have testing sooner than those who do not (Hesse-Biber & An, 
2016). Women also tend to factor in social factors when making decisions concerning 
their genetic testing and management (Hesse-Biber & An, 2016). Women are more likely 
to postpone genetic testing if they perceive themselves to have strong social supports 
(Hesse-Biber & An, 2016). For women who are not yet affected, the decision to pursue 
genetic testing for an adult-onset disease such as hereditary breast cancer is hypothesized 
to partially be a coping mechanism to combat the uncertainty of living at risk of 
developing a disease at some point in the future and to obtain control over an otherwise 
minimally controllable situation (Gooding et al., 2005) 
  1.3.2 Patient Demographics 
Education has been found to be a predictor of women’s awareness of and interest 
in genetic testing for hereditary cancer syndromes. Women who obtain higher levels of 
education are more likely to report awareness of genetic testing services for cancer (Mai 
et al., 2014; Tambor, Rimer, & Strigo, 1998). Reported interest in pursuing genetic 
counseling and testing services is also associated with higher levels of education (Culver 
et al., 2001; Lerman et al., 1994).  
There are significant differences in the ethnic composition of women who choose 
to pursue genetic testing for cancer. Ethnic minorities are less likely to be aware of 
genetic testing services and less likely to refer themselves to genetic counseling (Mai et 
al., 2014; Glenn, Chawla, & Bastani, 2012; Hutson, 2003). While it is hypothesized that 
the mutation prevalence of the BRCA genes is similar across ethnicities, women of 
European ancestry make up the majority of consumers of genetic testing services, while 
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women of African, Asian, and Latina ancestry comprise a smaller portion, even when 
their numbers are combined (Hall et al., 2009; Susswein et al., 2008). Minority women 
tend to face more socioeconomic barriers to accessing genetic services, such as time 
limitations, difficulty accessing providers and referrals, geographic barriers, and language 
barriers (Forman & Hall, 2009; Thompson et al., 2003). Ethnicity and race also play a 
role on women’s attitudes and perspectives on cancer genetic testing. Minority 
populations typically have greater levels of distrust in the medical community.  Latina 
and African American women have previously been shown to be more concerned about 
testing abuses of genetic information when compared to Caucasian women (Glenn, 
Chawla, & Bastani, 2012; Thompson et al., 2003).  
Income and insurance coverage both play a role in determining how likely a 
woman is to pursue genetic testing. Women who have higher income and utilize some 
form of health insurance are more likely to have had genetic testing (Lerman et al., 1996). 
Women who have lower incomes are more likely to agree with perceived disadvantages 
of genetic testing, such as fear of confidentiality, concern about the impact the result may 
have on the family, and a fear of being singled out, among others (Thompson et al., 
2003). Recent research has suggested that women in low income communities are 
interested in receiving genetic counseling and testing, but face challenges related to 
access (Komenaka et al., 2015). 
Whether a person lives near an urban community or within a rural community 
predicts their awareness of and access to genetic testing services.  Physicians in rural 
practices are less likely to refer for hereditary breast cancer than physicians practicing in 
	 9 
urban or suburban locations, due to distance, lack of awareness, lack of effective cancer 
risk reduction, and lack of patient interest (Koil et al., 2003).  
 
  1.3.3 Genetic Testing: Climate Changes Impacting Awareness and Interest 
The Genetic Information Nondiscrimination Act (GINA) was approved in 2008.  
The main purpose of GINA was to prevent insurance companies and employers from 
discriminating based on genetic testing results (Feldman, 2012). Violations of GINA are 
punishable by monetary penalty. (Erwin, 2008). Misuse of genetic testing in the 1970s to 
discriminate against African Americans with sickle cell disease in the workplace and 
through insurance coverage fostered a mistrust of the clinical use of genetic information, 
and still remains a serious concern of many citizens today (Feldman, 2012). GINA was 
developed to encourage patients to receive genetic testing when it is deemed to be a 
helpful investigative tool to manage their health care, without fear of this information 
being used against them in the future. While knowledge about GINA is associated with a 
reduction in concern regarding health insurance discrimination, consumer knowledge 
about GINA is still limited (Allain, Friedman, & Senter, 2012). 
The Patient Protection and Affordable Care Act (ACA) became law in 2010, and 
was fully implemented on January 1, 2014.  One of the main purposes of the ACA was to 
guarantee access to universal, affordable, health insurance coverage. In 2007, an 
estimated 56 million American citizens were considered “medically disenfranchised”, 
meaning that their most basic health and wellness needs were not being met (National 
Association of Community Health Centers, 2007). The ACA is projected to double the 
number of patients who are medically served (Rosenbaum, 2011).  Furthermore, the ACA 
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allows for the reduction of the cost and the provision of Medicaid coverage for clinical 
preventative services, including advanced screening and genetic counseling and testing 
for women who are at high risk of developing breast cancer. (Koh & Sebelius, 2010). 
However, the ACA does not provide coverage for all screening techniques recommended, 
even for women with a known BRCA1/2 mutation, raising concerns that the coverage of 
genetic testing alone would have limited benefit in vulnerable populations (Walcott et al., 
2014). 
In 2013, awareness of genetic testing, for the BRCA genes specifically, increased 
dramatically due to media coverage of celebrity Angelina Jolie’s essay sharing her 
experiences with genetic testing and her subsequent decision to have a prophylactic 
mastectomy (Evans et al., 2014).  The aftermath of this event led to global increases in 
referrals to genetic testing services and in requests for BRCA1/2 testing (Evans et al., 
2014).  Women who identified with Jolie in some way were found to be especially 
motivated to pursue genetic testing (Kosenko, Binder, & Hurley, 2016). In general, 
research suggests that celebrity experience and endorsement raises positive public 
perception of the subject and increases information seeking behaviors (Hoffman & Tan, 
2013). 
Studies have suggested that up to 50% of female BRCA mutation carriers have no 
significant family history of suggestive of HBOC (Moller et al., 2007).  Based on current 
guidelines, these females would not be considered suitable candidates for genetic testing 
until they themselves had an early cancer diagnosis, removing the option of prophylactic 
action. Population screening for BRCA1/2 has been proposed as a possible alternative to 
capture this population (Gabai-Kapara et al., 2014).  Population screening has been 
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shown to be more cost-effective than family-history based approaches, but will still prove 
to be a costly and time-consuming process in a multi-million-person population such as 
the United States (Manchanda et al., 2015; Clain et al., 2015). General population 
screening of BRCA1 and BRCA2 may be a cost effective option to identify carriers, and 
seems to be a possibility within our grasp as small-scale implementations are already in 
effect (Wang, 2016).  
 
1.4 Health Belief Model  
The Health Belief Model (HBM) was created out of psychological and behavioral 
theory in 1952 as a measure to assess factors impacting the utilization of preventative 
health services, such as screening and immunizations (Rosenstock, 1974). The original 
HBM consisted of four key dimensions – perceived susceptibility of developing a 
condition, perceived severity of the condition, perceived benefits of preventative action 
and perceived barriers to preventative action (Janz & Becker, 1984). The interactions of 
each component are summarized in Figure 1.  
Perceived susceptibility encompasses a range of perceptions of risk from complete 
denial to imminent risk (Strecher & Rosenstock, 1997).  Some individuals without a 
family history of breast cancer may not feel that they are susceptible to cancer 
themselves. Other individuals with a family history of breast cancer may feel that they 
are highly likely to develop breast cancer themselves.  Perceived severity is defined as an 
individual’s assessment of the impact a diagnosis or condition may have on their lifestyle 
and emotional being (Strecher & Rosenstock, 1997). Perceived benefits, or the positive 
aspects of particular actions, may include physical and psychosocial gains and may  
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Figure 1.1 The Health Belief Model (Becker, 1974) 
influence actions related to management (Strecher & Rosenstock, 1997).  Lastly, 
perceived barriers, or the negative aspects of an action, may include financial costs, 
inconvenience, or pain incurred by the action and also may influence actions (Strecher 
&Rosenstock, 1997). Previous studies utilizing the HBM to examine women’s attitudes 
and perceptions towards BRCA1/2 testing have shown a relationship between perceived 
susceptibility, perceived severity, and concerns about being a mutation carrier with 
testing decisions (Wang et al., 2007). Women who tend to be more concerned about 
being mutation carriers, and report high perceived susceptibility and low perceived 
severity were found to be more likely to undergo genetic testing (Wang et al., 2007). 
Women who perceived the benefits of testing to be high were more likely to pursue 
genetic testing that women who perceived the benefits of testing to be low (Wang et al., 
2007). 
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In the HBM, perceived susceptibility and severity are thought to motivate an 
individual to action. The reduction of perceived barriers is thought to provide easier 
accessibility for an action.   If an individual believes they are at high risk for a health 
issue, such as developing breast cancer, an action to reduce risk is not likely to take place 
unless the individual believes there are substantial benefits associated with their efforts 
(Strecher & Rosenstock, 1997).  Therefore, expressed interest in utilizing preventative 
services, such as BRCA1/2 genetic testing may be related to whether or not the perceived 
benefits of this action outweigh the perceived risks. 
Along with the original four items of the Health Belief Model, perceptions of self-
efficacy, or belief in one’s ability to successfully navigate tasks and challenges, have 
been proposed as an independent variable to partially explain interest in preventative 
health behavior (Rosenstock et al., 1988). Individuals must not only feel that the benefits 
of preventative action would outweigh the costs, but also feel that they are competent to 
overcome perceived barriers to take action. 
 
1.5 Rationale 
The first objective of this study is to identify factors that predict women’s interest 
in genetic testing for hereditary breast cancer syndromes. Previous literature suggests that 
women thought to be at risk for breast cancer based on their family history may benefit 
from pursuing genetic testing. Genetic counseling and subsequent testing for cancer-
predisposing mutations is linked to increased screening behaviors, which help early 
diagnosis and management of cancer if it does develop (Botkin et al., 2003). Genetic 
testing may promote patient empowerment as some women report feeling more control 
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over their health after deciding to pursue genetic testing (Gooding et al., 2005).  Many 
studies following the initial rise in commercialized genetic testing suggested that 
education and perceived risk of developing breast cancer were the biggest predictors in 
women’s reported interest in genetic testing services, despite ethnicity and income. 
African American women and Hispanic women of low socioeconomic status have 
reported high interest in learning more about cancer genetic testing (Komenka et al., 
2015).  
However, literature has also shown that these services are primarily utilized by 
women who have had more education, have greater annual household incomes, have 
some form of health insurance, and are Caucasian (Lerman et al., 1996) Currently, 
services are reported to be underutilized by ethnic or racial minorities and women with 
lower socioeconomic statuses, despite the fact that hereditary breast cancer is no more or 
less likely to affect these populations, and is more likely to be the cause of death if it does 
develop either due to later diagnoses or more aggressive manifestations. The second goal 
of this study will be to attempt to clarify whether or not services are underutilized by 
these populations because they are unaware of these services or if the perceived utility of 
genetic testing in these populations is not high enough to outweigh concerns related to 
accessibility and psychological impact, or possibly a combination of the two.  
The third goal of this study is to compare historical factors that predict interest in 
genetic testing to those that are expressed in this study.  Since the first utilization of 
breast cancer genetic testing, many aspects of this process have changed.  Legislation has 
now made genetic testing more affordable by making it possible to be covered by public 
insurance.  Genetic information is now protected by law, potentially alleviating fears of 
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discrimination and stigma.  Celebrity use and publication of experiences with genetic 
testing have increased awareness of services and aided in normalizing the process.  These 
factors together suggest that there may be differences in the way the general population 
of women now perceives genetic testing than they might have in its early days. The 
healthcare barriers and perceived disadvantages that women feel concerning genetic 
testing in 2016 may be very different than those that were identified in the early 2000s. 
Despite all that has changed since BRCA testing was first commercialized in 1996 
to make this service more accessible to underserved populations, research suggests that 
vulnerable and historically discriminated against populations still are not utilizing genetic 
testing services at as great a frequency (Glenn, Chawla & Bastani, 2012). However, in 
previous studies, women in these communities have expressed interest in these services. 
This raises a question of what factors are specifically preventing women from seeking 
genetic testing. Therefore, we hypothesize that while participants of all backgrounds will 
express similar levels of interest in genetic testing services, women from underserved 
populations will be more likely to cite concerns regarding accessibility and utility, and 
less likely to agree with the proposed benefits of genetic testing.  
  1.51 Potential Risks  
 A potential concern of this study is that presenting the risk of breast cancer may 
raise individual’s anxiety concerning their chance of having a hereditary cancer 
syndrome.  To address this, participants were provided with a fact sheet containing 
instructions for contacting a local genetic counselor if they find themselves experiencing 
increased anxiety about their personal risk of having a hereditary cancer syndrome 
(Appendix A). Information gained from this study may not benefit the participants 
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directly. However, the results of the study may benefit current and future patients with 
hereditary breast cancer syndromes. Information gleaned from participants’ responses 
will aide in developing educational tools and outreach strategies to better include 
underserved populations.  
1.6 Purpose  
The current study explores the attitudes and beliefs of women across demographic 
characteristics concerning genetic testing for hereditary breast cancer.  The first goal of 
this study is to identify factors that predict women’s interest in genetic testing for 
hereditary breast cancer. The second goal of this study is to clarify women’s perceptions 
of the personal and clinical utility of genetic testing for hereditary breast cancer.  The 
third goal of this study is to compare factors that predict interest in genetic testing for 
hereditary breast cancer in this population against factors that have predicted interest in 
previous studies. This study aims to provide insight into women’s perceived utility and 
knowledge of genetic testing services.  It also aims to identify populations that may 
benefit from further education about hereditary breast cancer genetic testing services, as 
well as what concepts and concerns educational outreach should address. 
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CHAPTER II. ASSESSING WOMEN’S ATTITUDES TOWARDS GENETIC 
TESTING FOR HEREDITARY BREAST CANCER1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Apostolico, T.J., Hill-Chapman, C.R., Heiney, S.P., & Murphy, R.T. To be submitted to 
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2.1 Abstract 
OBJECTIVES: Hereditary Breast and Ovarian Cancer (HBOC) is an autosomal dominant 
cancer predisposition syndrome with a 46-87% lifetime risk of breast cancer.  Unaffected 
women who have HBOC are eligible for more screening procedures and prophylactic 
surgeries that may reduce the risk of developing cancer by up to 95%. The objectives of 
this study were to assess women’s awareness of and interest in breast cancer genetic 
testing services, as well as women’s attitudes and beliefs regarding the clinical utilization 
of HBOC genetic testing across demographic categories. METHODS: Two-hundred and 
sixty-eight women completed a 35-item survey designed to capture perceptions of HBOC 
and genetic testing, attitudes towards genetic testing for HBOC, and demographics. 
RESULTS: Two-hundred and eight women met participation criteria. One-hundred and 
fifty-five (75%) indicated prior awareness of genetic testing services. One-hundred and 
forty-three (69%) indicated interest in genetic testing for HBOC. Black women, women 
with lower levels of education, and women with lower household incomes reported less 
awareness, but similar levels of interest in genetic testing services when compared to 
other participants.  CONCLUSIONS: Women are interested in genetic testing for HBOC. 
Specific counseling on barriers to minority and low socioeconomic communities, such as 
cost and education regarding genetic testing procedures, may be beneficial in increasing 
utilization of genetic testing for HBOC in these communities. Women who experience 
more discrimination may have increased perceptions of their susceptibility to hereditary 
cancer syndromes and may benefit from personalized risk counseling. 
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2.2 Introduction 
 Hereditary Breast and Ovarian Cancer (HBOC) is an autosomal dominant cancer 
predisposition syndrome caused by germline mutations in the breast cancer 1 (BRCA1) 
and breast cancer 2 (BRCA2) tumor suppressor genes. Individuals who have a pathogenic 
gene mutation in either BRCA1 or BRCA2 have a 46-87% life time risk of developing 
breast cancer, compared to a general population risk of 12% (National Cancer Institute, 
2016). A prophylactic bilateral mastectomy in mutation carriers has been found to reduce 
the risk of breast cancer by at least 90% (Hartmann et al., 2001).  
Women who are determined to have a high risk of developing breast cancer, 
either by known genetic variant or family history, are eligible and encouraged to seek 
high-risk screening procedures to decrease this risk (National Comprehensive Cancer 
Network, 2016). These procedures, including earlier and more frequent utilization of 
physical examinations and imaging techniques, have been shown to detect a larger 
number of cases of breast cancer at an earlier stage of disease (DeSantis et al., 2013; Berg 
et al., 2012). Women found to be at higher risk of developing breast cancer are also 
offered the option of having a risk reducing prophylactic procedure, such as a 
mastectomy, which may reduce the risk of breast cancer by as much as 90-95% (Rebbeck 
et al., 2004). 
Genetic testing for a hereditary breast cancer mutation has multiple proposed 
benefits. Asymptomatic patients who learn they have a mutation that increases their risk 
of developing breast cancer can begin to follow high-risk screening regimens to promote 
early detection, and may consider risk reducing surgeries (Scheuer et al., 2002). 
Receiving genetic counseling and testing, whether the result is positive or negative, has 
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been shown to increase utilization of mammography and breast self-exams post result 
disclosure (Botkin et al., 2003).  
Historically, genetic testing services have been underutilized by individuals who 
are minorities and individuals who are in lower socioeconomic classes (Glenn, Chawla, 
& Bastani, 2012; Thompson et al., 2003).  Women reporting higher levels of education 
are more likely to report awareness and interest in genetic testing services (Lerman et al., 
1994). However, within the past decade the climate surrounding genetic testing has 
shifted, potentially increasing not only the general population’s awareness of genetic 
testing services but also their ability to access these services. Our study aimed to 
determine women’s awareness of and interest in breast cancer genetic testing services, as 
well as women’s attitudes and beliefs regarding the potential clinical and personal 
utilization of genetic testing for HBOC across multiple demographic categories. 
 
2.3 Materials and methods 
  2.3.1 Design and participants  
 Women, age 18 or older, who had not yet undergone genetic testing for hereditary 
breast cancer syndromes in the United States were surveyed. Potential participants were 
required to meet eligibility criteria in order to proceed with the questionnaire to confirm 
that only the opinions of the targeted population would be captured by the study. Males 
were excluded from this study as the cancer risks and medical management 
recommendations differ significantly between male and female BRCA1/2 carriers.  
Women who had already undergone genetic testing for hereditary cancer syndromes were 
excluded from the study as their opinions concerning benefits and barriers would have 
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already been informed by the testing and counseling process.  Women who were not from 
the United States were excluded as other countries not only differ in their guidelines and 
recommendations, but also in their national health insurance programs. Individuals who 
met exclusionary criteria were disqualified from participating in the questionnaire via the 
skip logic function of the questionnaire programming software provided by 
SurveyMonkey.com. Based upon G* power program, we determined that at a statistical 
significance level of !=0.05, we would require 60 participants. The threshold for G* 
power was exceeded for all statistical analyses.  
Responses were collected from November 1st, 2016 to February 8th, 2017. In order 
to capture a diverse sample, women were invited to participate through three channels: 
Facebook.com, student classes, and homeless shelters.  The invitation to participate can 
be found in Appendix B.  Individuals were invited to participate in the study through the 
social network, Facebook.com. Students enrolled in Introductory Biology, Introductory 
Chemistry, Introductory Nursing, and Introductory Psychology at a small public liberal 
arts college in the southeastern United States were invited to participate in the study in 
return for extra credit in their coursework. Individuals utilizing services provided by 
shelters assisting those in need in South Carolina were also invited to participate verbally 
in return for a $5 food coupon.  Signed letters of support were obtained from directors of 
any shelter that participated prior to the distribution of the questionnaire (Appendix C).  
A flyer advertising the study and providing standardized background information on 
hereditary cancer and genetic counseling was distributed to women at the shelter 
(Appendix D). Women who expressed interest in completing the questionnaire sat in 
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private with the principle investigator, who assisted the participants in reading the 
background information and questionnaire, and documenting responses. 
  2.3.2 Instrument 
 An original questionnaire utilizing skip logic was developed through 
SurveyMonkey.com. The questionnaire (Appendix E) was constructed by the principle 
investigator and contained thirty-five quantitative items used to measure categorical 
information from the participants. This measure was reviewed and edited by all members 
of the committee for face validity. The questionnaire utilized a series of multiple choice 
questions designed to assess the participant’s prior awareness of breast cancer genetic 
testing services and interest in genetic testing for hereditary breast cancer. One 
continuous item was utilized to elucidate participants’ perceptions of their cancer risk 
(Gurmenkin Levy et al., 2006). Validated scales were utilized to ascertain participants’ 
perceived self-efficacy (Schwarzer & Jerusalem, 1995), perceptions of daily 
discrimination (Krieger et al., 2005), and prior general knowledge regarding BRCA1/2 
(Lerman et al., 1996). The questionnaire contained a version of the Health Belief Model 
(HBM) modified specifically for this questionnaire to assess perceived susceptibility and 
severity of hereditary breast cancer, and perceived benefits and barriers of preventive 
genetic testing (Wang et al., 2007; Jacobsen et al., 1997).  
 Cronbach’s alpha scores were calculated for each scale. For the perceived self-
efficacy scale, ! = 0.99. For the daily discrimination scale, ! = 0.71. For the perceived 
susceptibility to hereditary breast cancer scale, ! = 0.80. For the perceived severity of a 
hereditary breast cancer scale, ! = 0.84.  For the proposed benefits scale, ! = 0.78, and 
for the proposed risks and barriers scale, ! = 0.61 As the Cronbach’s alpha calculated 
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for participants’ prior knowledge of hereditary breast cancer was ! < 0.50, these items 
were not analyzed as a scale and instead analyzed separately.  
 Demographic information including age, gender, race, level of education, 
relationship status, region of residence in the United States, number of children, annual 
household income, and current method of health insurance was obtained.  The survey 
also contained questions specific to breast cancer, including personal and family histories 
of breast cancer and genetic testing in order to better characterize whether or not the 
participant would be considered at high risk of having a hereditary cancer syndrome. The 
demographic and categorical data provided variables for statistical analysis. 
Prior to beginning the questionnaire, all participants were provided with a brief 
and succinct definition of hereditary breast cancer and genetic counseling (Appendix D). 
Consent agreement was provided on the first page of the questionnaire in accordance 
with the protocol approved by the University of South Carolina Institutional Review 
Board. 
  2.3.3 Data Analysis  
For quantitative data analysis, responses were compared as a whole, as well as 
divided into groups for further investigation. Data analysis was performed using 
Statistical Package for the Social Sciences, Version 24.  One-way ANOVA tests 
examined the statistical significance (p < 0.05) of associations between demographic 
factors and levels of interest and awareness of genetic testing services. Spearman and 
Pearson correlations were utilized to further explain associations between variables such 
as age and education and awareness of and interest in genetic testing for hereditary breast 
cancer. 
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To analyze responses to the HBM, average ratings were calculated for each item 
regarding perceptions of disease susceptibility and severity, and the benefits and barriers 
of testing using the Likert scale format (strongly disagree = 1; disagree = 2; agree = 3; 
strongly agree = 4). Mann-Whitney U tests were used to examine the statistical 
significance of associations between reported awareness and interest in genetic testing 
services and items of the HBM.  Kruskal-Wallis H tests were used to examine the 
statistical significance of associations between reported demographic factors and items of 
the HBM. 
 
2.4 Results 
  2.4.1 Demographic Information 
 Of the 268 responses to the four-item section of the questionnaire that determined 
eligibility, 238 responses met criteria. Ineligible participants included men (n = 6), 
minors (n = 4), individuals who had already had genetic testing for BRCA1/2 (n = 17), 
and individuals who lived outside of the United States (n = 3). Of those who met criteria, 
30 did not complete more than 80% of the survey and were excluded from data analysis, 
resulting in a total of 208 eligible responses.   
 Of the 208 responses, 65% of participants described themselves as non-Hispanic 
white (n = 135) and 26% of participants described themselves as black (n = 54).  The 
average age of participants was 34.11 with a range of 18 to 65 years of age and a standard 
deviation of 14.86.  The majority of participants reported receiving a Bachelor’s degree 
or higher (n = 121). 64.4% of participants reported utilizing employer-provided health 
insurance (n = 134). The majority of participants were single (n = 93), had no children (n 
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= 119), and lived in the eastern region of the United States (n = 177). Participants had a 
mode annual household income reported between $125,000 to $149,999 (n = 17).  
Demographics of individual respondents are shown in Table 2.1 
  2.4.2 Awareness of Genetic Testing Services 
 The majority of participants (74.5%) indicated that prior to this survey they were 
aware of genetic testing services for hereditary breast cancer. Statistical significance (p < 
0.05) was noted in differences between average awareness of services within multiple 
demographic factors, including race, highest level of education, health insurance 
coverage, and annual household income. A demographic comparison of women who 
reported awareness and those who did not can be found in Table 2.2.  
Black women were statistically significantly less likely to have heard of genetic 
testing for hereditary breast cancer than non-Hispanic white women (p = 0.03).  Women 
who reported utilizing government-provided health insurance were less likely to be aware 
of services than women who reported utilizing employer provided private insurance (p < 
0.01). Women who reported an annual household income of less than $10,000 were less 
likely to be aware of services than women who reported an annual income of $200,000 or 
more (p = 0.03).  
Age had a weak but statistically significantly relationship to awareness of genetic 
testing services (r = 0.23, p < 0.01). Younger women were less likely to be aware of 
services than older women. Education also had a moderate but statistically significantly 
correlation with awareness of testing services. Women who reported obtaining higher 
levels of education were more likely to be aware of genetic testing services than those 
who reported lower levels of education (r = 0.33, p < 0.01). 
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Table 2.1 Participant demographic information 
	
Individual Participant N = 
208 
(%) Individual Participant N = 
208 
(%) 
 
Race   Marital Status   
     Asian 10 (4.9)      Married 82 (39.4) 
     Black American 54 (26.2)      Divorced/Separated 7 (3.4) 
     Hispanic 7 (3.4)      Cohabitating 26 (12.5) 
     Non-Hispanic White 135 (65.5)      Single 93 (44.7) 
Highest Education   No. of children   
     Less than high school 2 (1.0)      0 children 119 (57.2) 
     High school/GED 30 (14.4)      1 child 10 (4.8) 
     Some college 50 (24.0)      2 children 37 (17.8) 
     Associate’s degree 5 (2.4)      3 children 20 (9.6) 
     Bachelor’s degree 76 (36.5)      4 or more children 19 (9.2) 
     Graduate degree 45 (21.6) Income    
Age        < $10,000 20 (9.6) 
     < 20 years 28 (13.5)      $10,000 - $24,999 11 (5.3) 
     20 – 24 years 69 (33.2)      $25,000 - $49,999  11 (5.3) 
     25 – 29 years 17 (8.2)      $50,000 - $74,999 23  (11.1) 
     30 – 34 years 4 (1.9)      $75,000 - $99,999 19 (9.1) 
     35 – 39 years 13 (6.3)      $100,000 - $124,999 14 (6.7) 
     40 – 44 years 8 (3.8)      $125,000 - $149,999 17 (8.2) 
     45 – 49 years 13 (6.3)      $150,000 - $174,999 7 (3.4) 
     50 – 54 years 32 (15.4)      $175,000 - $199,999 5 (2.4) 
     55 – 59 years 18 (8.7)      > $200,000 48 (23.1) 
     60 – 64 years 5 (2.4)      Prefer not to answer 33 (15.9) 
     > 65 years 1 (0.5) Residency   
Insurance        Northeast2 87 (41.8) 
     Uninsured 9 (4.3)      Southeast3 90 (43.3) 
     University provided 16 (7.7)      Midwest4 6 (2.9) 
     Government provided1 20 (10.6)      Northwest5 1 (0.5) 
     Self-provided private 28 (13.5)      Southwest6 5 (2.4) 
     Employer private 134 (64.4)      Did not specify 19 (9.1) 
1Includes Medicaid and Medicare 
2Includes ME, VT, NY, NH, MA, RI, CT, NJ, PA, DE, MD, DC 
3Includes VA, WV, KY, TN, NC, SC, GA, FL, MS, AL, Puerto Rico 
4Includes OH, IN, MI, IL, WI, MN 
5Includes WA, OR, ID, MT, AK, WY, CO 
6Includes TX, NM, AZ, NV, UT, CA, HI
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 Table 2.2 Demographic comparison of aware versus unaware individuals 
 Aware Individuals Unaware Individuals Group Total 
 n = 155 (%) n = 53 (%) N 
Race      
    Asian 9 (90.0) 1 (10.0) 10 
    Black American 32 (59.3) 22 (40.7) 54 
    Hispanic 6 (85.7) 1 (14.3) 7 
    Non-Hispanic White 107 (79.3) 28 (20.7) 135 
Highest Education      
    Less than high school 1 (50.0) 1 (50.0) 2 
    High school/GED 14 (46.7) 16 (53.3) 30 
    Some college 32 (64.0) 18 (36.0) 50 
    Associate’s degree 4 (80.0) 1 (20.0) 5 
    Bachelor’s degree 64 (84.2) 12 (15.8) 76 
    Graduate degree 40 (88.9) 5 (11.1) 45 
Age      
    < 20 years 15 (53.6) 13 (46.4) 28 
    20 – 29 years 59 (68.6) 27 (31.4) 86 
    30 – 39 years 16 (94.1) 1 (5.9) 17 
    40 – 49 years 16 (76.2) 5 (23.8) 21 
    50 – 59 years 43 (86.0) 7 (14.0) 50 
    > 60 years 6 (100.0) 0 (0.0) 6 
Income       
    < $10,000 9 (45.0) 11 (55.0) 20 
    $10,000 - $24,999 8 (72.7) 3 (27.3) 11 
    $25,000 - $49,999  8 (72.7) 3 (27.3) 11 
    $50,000 - $74,999 13 (56.5) 10 (43.5) 23 
    $75,000 - $99,999 14 (73.7) 5 (26.3) 19 
    $100,000 - $124,999 13 (92.9) 1 (7.1) 14 
    $125,000 - $149,999 13 (76.5) 4 (23.5) 17 
    $150,000 - $174,999 5 (71.4) 2 (28.6) 7 
    $175,000 - $199,999 4 (80.0) 1 (20.0) 5 
    > $200,000 41 (85.4) 7 (14.6) 48 
    Prefer not to answer 27 (81.8) 6 (18.2) 33 
Health Insurance      
    Uninsured 6 (66.7) 3 (33.3) 9 
    University-provided 10 (62.5) 6 (37.5) 16 
    Government-provided1 8 (40.0) 12 (60.0) 20 
    Self-provided private 20 (71.4) 8 (38.6) 28 
    Employer-provided private 110 (82.1) 24 (17.9) 134 
1Includes Medicare and Medicaid  
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2.4.3 Interest in Genetic Testing for Hereditary Breast Cancer  
 The majority of participants (68.75%) indicated they would be interested in 
pursuing genetic testing for hereditary breast cancer.  One-way ANOVAs showed 
statistical significance (p < 0.05) between reported average interest within multiple 
demographic factors, including marital status and number of children. Married woman 
were statistically significantly less likely to report interest in testing than woman who had 
never been married (p < 0.01). Women who reported having no children were statistically 
significantly more likely to report interest in genetic testing for hereditary breast cancer 
than those who reported having 2 or more children (p < 0.01). Race did not have a 
statistically significantly association with interest in testing. However, a considerable 
trend towards significance was noted in that black women tended to be more likely to 
report interest in testing than non-Hispanic white women (p = 0.051).  
Age had a moderate but statistically significantly relationship with interest in 
testing services (r = -0.32, p = 0.01), with younger women more frequently expressing 
interest in genetic testing for hereditary breast cancer. Highest level of education was 
found to have a weak but statistically significantly correlation with interest (r = -0.17, p = 
0.01), with women who reported obtaining higher levels of education less frequently 
reporting interest than other participants.  Women’s perceptions of their risk of 
developing breast cancer was not statistically significantly associated with interest in 
genetic testing.  
 Women who reported interest in genetic testing were statistically significantly 
more likely to perceive themselves to be at risk for a genetic mutation that would 
predispose them to breast cancer (p < 0.01). Interested participants were also more likely 
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to agree or strongly agree with the proposed benefits of genetic testing than those who 
were not interested (p < 0.01). Interested participants reported statistically significantly 
higher frequencies of day to day discrimination (p < 0.01). Prior awareness of testing 
services was not found to be statistically significantly associated with interest. There was 
no statistically significant difference between interested participants and uninterested 
participants concerning perceptions of the severity of a genetic predisposition to cancer, 
overall perceptions of barriers to genetic testing, perceptions of self-efficacy, and general 
knowledge of hereditary breast cancer. A comparison of the demographics of interested 
and uninterested participants can be found in Table 2.3.  
  2.4.4 Health beliefs 
Table 2.4 represents 20 items that were derived from the HBM.  The data was 
generated by the Likert scale rating format to determine individual perceptions of the 
susceptibility to and the severity of a genetic mutation that would increase their risk of 
breast cancer, as well as the benefits and barriers of preventative testing for BRCA1/2 
pathogenic variants.  A high average is associated with agreement (strongly agree = 4) to 
a statement, whereas a low average is associated with disagreement (strongly disagree = 
1). Items were compared among demographic groups, analyzed, and averaged. 
 In general, women reported high agreement to the proposed benefits of genetic 
testing and low agreement to the proposed barriers of genetic testing (Figures 2.1 & 2.2). 
The most strongly agreed with benefits included learning about their children’s risk for 
breast cancer, informing action regarding dealing with cancer risk, and helping other 
family members decide whether to test.  Women disagreed most strongly with the 
proposed barriers that their family would not be supportive, testing would not cause them  
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Table 2.3 Demographic comparison of interested versus uninterested individuals 
 
 Interested Individuals Uninterested Individuals Group Total 
 n = 143 (%) n = 65 (%) N 
Race      
    Asian 6 (60.0) 4 (40.) 10 
    Black American 45 (83.3) 9 (16.7) 54 
    Hispanic 5 (71.4) 2 (28.6) 7 
    Non-Hispanic White 86 (63.7) 49 (36.3) 135 
Highest Education      
    Less than high school 2 (100.0) 0 (0.0) 2 
    High school/GED 21 (70.0) 9 (30.0) 30 
    Some college 43 (86.0) 7 (14.0) 50 
    Associate’s degree 4 (80.0) 1 (20.0) 5 
    Bachelor’s degree 46 (60.5) 30 (39.5) 76 
    Graduate degree 27 (60.0) 18 (40.0) 45 
Age      
    < 20 years 20 (71.4) 8 (28.6) 28 
    20 – 29 years 73 (84.9) 13 (15.1) 86 
    30 – 39 years 13 (76.5) 4 (24.5) 17 
    40 – 49 years 11 (52.4) 10 (47.6) 21 
    50 – 59 years 23 (46.0) 27 (54.0) 50 
    > 60 years 3 (50.0) 3 (50.0) 6 
Income       
    < $10,000 14 (70.0) 6 (30.0) 20 
    $10,000 - $24,999 8 (72.7) 3 (27.3) 11 
    $25,000 - $49,999  7 (63.7) 4 (36.4) 11 
    $50,000 - $74,999 18 (78.3)) 5 (21.7) 23 
    $75,000 - $99,999 15 (78.9) 4 (21.1) 19 
    $100,000 - $124,999 9 (64.3) 5 (35.7) 14 
    $125,000 - $149,999 11 (64.7) 6 (35.3) 17 
    $150,000 - $174,999 6 (85.7) 1 (14.3) 7 
    $175,000 - $199,999 3 (60.0) 2 (40.0) 5 
    > $200,000 26 (54.2) 22 (45.8) 48 
    Prefer not to answer 26 (78.8) 7 (21.2) 33 
Health Insurance      
    Uninsured 8 (88.9) 1 (11.1) 9 
    University-provided 11 (68.7) 5 (31.3) 16 
    Government-provided1 14 (70.0) 6 (30.0) 20 
    Self-provided private 19 (67.9) 9 (32.1) 28 
    Employer-provided private 90 (67.2) 44 (32.8) 134 
1Includes Medicare and Medicaid    
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Table 2.4 Health Belief Model and comparison of groups 
 All 
Participants 
Aware 
Individuals 
Unaware 
Individuals 
 Interested 
Individuals 
Uninterested 
Individuals 
 
 N = 208 n = 155 n = 53 p n = 143 n = 65 p 
Perceptions of susceptibility 2.0944 2.13635 1.9519  2.2183 1.8047 <0.01 
Perceptions of severity 2.8476 2.8538 2.8302  2.8718 2.7949  
Benefits        
    Learn about children’s risk for breast cancer 3.1990 3.1623 3.3077  3.2676 3.0469 0.02 
    Help other family members decided whether to test 3.0386 3.0260 3.0755  3.1469 2.7969 <0.01 
    Ease my mind, regardless of test result 2.5865 2.5290 2.7547  2.6993 2.3385 <0.01 
    Inform action regarding dealing with cancer risk  3.1463 3.1307 3.1923  3.2746 2.8571 <0.01 
    Help me reduce uncertainty about the future 2.7902 2.7647 2.8654  2.9149 2.5156 <0.01 
    Help me make important life decisions  2.5099 2.4901 2.5686  2.6170 2.2623 <0.01 
    Provide a sense of personal control 2.9565 2.9481 2.9811  3.0563 2.7385 <0.01 
Barriers        
    May not be able to cope with the result 2.1359 2.1176 2.1887  2.1408 2.1250  
    Do not understand what will be done 1.9275 1.8701 2.0943  2.0350 1.6875 <0.01 
    Would not do anything different to manage cancer risk 1.8019 1.8247 1.7358  1.7203 1.9844 <0.01 
    Would have a negative impact on family 1.8641 1.8824 1.8113  1.8028 2.0000 0.03 
    Cannot afford the cost 2.4975 2.4342 2.6863  2.5929 2.2857 0.02 
    Family would not be supportive 1.5700 1.5649 1.5849  1.5664 1.5781  
    Testing may lead to discrimination 1.9712 2.0129 1.8491  1.9371 2.0462  
    Testing would not provide new information 1.8317 1.8710 1.7170  1.7622 1.9846 0.03 
Statistically significant differences between groups appear in bold type, p < 0.05 
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Figure 2.1 Agreement with benefits of genetic testing 
 
 
 
Figure 2.2 Agreement with barriers of genetic testing 
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to do anything different to manage their cancer risk, and testing would not provide new 
information. Women only agreed with one proposed barrier, that they would not be able 
to afford the cost of testing.  
Interest strongly influenced women’s perceptions of susceptibility, benefits, and 
barriers to genetic testing for hereditary cancer (Table 2.4). Women who were interested 
in testing were more likely to perceive themselves as susceptible to a genetic mutation 
that would predispose them to breast cancer (p < 0.01). Interested participants agreed 
more strongly with all proposed benefits to genetic testing (p < 0.01). Interested women 
statistically significantly agreed more with the statement “I am afraid to undergo genetic 
testing because I do not understand what will be done” (p < 0.01), and the statement “I 
cannot afford the cost of genetic testing” (p = 0.02).  Women who were not interested in 
testing agreed statistically significantly more than interested women with a few barriers 
to genetic testing, including the statements, “Genetic testing will not help me because I 
would not do anything different to manage cancer risk” (p < 0.01), “Genetic testing will 
have a negative impact on my family” (p = 0.03), and “Genetic testing will not tell me 
anything new about my risk I do not already know” (p = 0.03). Interest had no 
statistically significant effect on women’s reports of perceptions of the impact a 
hereditary breast cancer syndrome would have on their lives or women’s reports of self-
efficacy. 
Age played a role in influencing women’s perceptions of the benefits and barriers 
to genetic testing.  Younger women were more likely to agree with the statement, 
“Genetic testing will help me make important life decisions” (p = 0.02). They more 
strongly agreed with a few barriers, including “I am afraid to undergo genetic testing 
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because I may not be able to cope with the result” (p < 0.01), “I am afraid to undergo 
genetic testing because I do not understand what will be done” (p < 0.01), and “I cannot 
afford the cost of genetic testing” (p < 0.01). 
 There were statistically significant differences in the benefits and barriers women 
most strongly agreed with between different racial groups (Figures 2.3 & 2.4).  Black 
women were statistically significantly more likely (p < 0.01) to agree with the statement 
“Genetic testing will help me make important life decisions” than non-Hispanic white 
women.  In terms of barriers, black women were more likely to agree with the statements, 
“I am afraid to undergo genetic testing because I may not be able to cope with the 
results” (p = 0.02), “I am afraid to undergo testing because I do not understand what will 
be done” (p < 0.01), and “I cannot afford the cost of genetic testing” (p < 0.01) than non-
Hispanic white women.  Asian women were statistically significantly more likely to 
agree with the statement “Genetic testing will not help me because I would not do 
anything different to manage my cancer risk” (p = 0.01) than Hispanic women. 
Highest level of education influenced women’s perceptions of the benefits and 
barriers to genetic testing for hereditary cancer. Women who reported receiving less than 
a bachelor degree were more likely to agree with the statement, “Genetic testing will help 
me make important life decisions” (p < 0.01) than those that reported receiving a 
bachelor’s degree.  Women who reported receiving less than a bachelor degree were also 
more likely to agree with the statements “I am afraid to undergo genetic testing because I 
may not be able to cope with the results” (p = 0.03), “I am afraid to undergo genetic 
testing because I do not understand what will be done” (p < 0.01), and “I cannot afford 
the cost of genetic testing” (p = 0.01). 
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Figure 2.3 Race vs. agreement with benefits 
 
Figure 2.4 Race vs. agreement with barriers
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 Marital status was similarly associated with perceptions of benefits and barriers 
regarding genetic testing for hereditary breast cancer.  Women who reported never being 
married were statistically significantly more likely to agree with the statements, “Genetic 
testing will help me make important life decisions” (p < 0.01), “I am afraid to undergo 
genetic testing because I may not be able to cope with the result” (p < 0.01), “I am afraid 
to undergo genetic testing because I do not understand what will be done” (p < 0.01), and 
“I cannot afford the cost for genetic testing” (p < 0.01) than women who reported that 
they were married. 
 Women who reported having no children were more likely to agree with the 
statements, “Genetic testing will help me make important life decisions” (p < 0.01). “I am 
afraid to undergo genetic testing because I may not be able to cope with the result” (p < 
0.01), “I am afraid to undergo genetic testing because I do not understand what will be 
done” (p < 0.01), and “I cannot afford the cost for genetic testing” (p < 0.01) than women 
who reported having two or more children. Women who reported having one child 
trended to being less likely to agree with the statement, “Genetic testing to learn my risk 
will help other family members decide whether to undergo testing” (p = 0.04) than 
women who reported having no children or more than one child. 
Participant’s reported insurance was only statistically significantly associated with 
increased agreement with barriers to genetic testing. Participants who reported utilizing 
government provided health insurance were more likely to agree with the statements “I 
am afraid to undergo genetic testing because I may not be able to cope with the results” 
(p < 0.01) than those that reported utilizing employer-provided health insurance.  These 
participants were also more likely to agree with the statement, “I am afraid to undergo 
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genetic testing because I do not understand what will be done” (p < 0.01) than 
participants reporting utilization of university-provided health insurance or employer 
provided health insurance. Participants who reported that they were currently uninsured 
or utilizing university-provided health insurance were statistically significantly more 
likely to agree with the statement, “I cannot afford the cost of genetic testing” (p < 0.01). 
Participants who reported utilizing employer-provided or self-provided private insurance 
more strongly agreed with the statement, “Genetic testing will not tell me anything new 
about my risk I do not already know” (p = 0.01) than those who reported utilizing 
university-provided health insurance. 
 Annual household income was also only statistically significantly associated with 
increased agreement with barriers to genetic testing.  Participants who reported annual 
household incomes of less than $10,000 were statistically significantly more likely to 
agree or strongly agree with the statement “I am afraid to undergo genetic testing because 
I do not understand what will be done” (p < 0.01) than participants who reported annual 
household incomes of greater than $200,000. Participants who reported annual household 
incomes of less than $125,000 were statistically significantly more likely to agree with 
the statement, “I cannot afford the cost for genetic testing” (p < 0.01) than participants 
who reported annual incomes of greater than $200,000.   
  2.4.5 Discrimination  
We examined our hypothesis that interest in genetic counseling would be lower 
for those who have higher reports of perceived discrimination.  Unexpectedly, 
participants who reported higher frequencies of daily discrimination also reported greater 
interest in genetic testing. To investigate our findings further, we examined the potential 
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mediating role of perceived susceptibility of a having inherited a genetic mutation that 
would predispose one to cancer between the relationship of perceived discrimination and 
interest in genetic counseling.  Although current perspectives on mediation propose that 
the requirements outlined by Baron and Kenny (1986) are unnecessary (Shrout & Bolger, 
2002), relations between our study variables did meet the expectations. Both the 
predictor, perceived discrimination, and the mediator, perceived susceptibility, were 
related to the outcome variable, genetic testing interest (Table 2.5). We present our 
findings in the conventional Baron and Kenny format for ease of interpretation.  
Table 2.5 Correlations between perceived discrimination, perceived susceptibility, 
and interest in genetic testing 
 
 1. 2. 3. 
Perceived Susceptibility -  .258** .173* 
Interest in Genetic Counseling  - .244** 
Perceived Discrimination   - 
  * Indicates p<0.05 
** Indicates p<0.01    
 
Using a multiple logistic regression, we regressed the criterion variable of interest 
in genetic testing on perceived discrimination in Step 1.  In Step 2, we regressed interest 
in genetic testing on both the predictor of perceived discrimination and on the proposed 
mediator of perceived susceptibility and saw a reduction in the strength of perceived 
discrimination to predict interest in genetic counseling.  The third regression equation 
provided an estimate of path c’, the relationship between perceived discrimination and 
interest in genetic counseling, controlling for perceived susceptibility.   When path c’ is 
zero, there is evidence of complete mediation. Path c’ was found to be reduced, and no 
longer statistically significant, suggesting partial mediation.  The R2adj = .05 for the final 
analysis indicated that almost 5% of the variability in interest in genetic counseling could 
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be accounted for by the mediation of perceived discrimination by perceived 
susceptibility. 
 We used the Sobel test to test the statistical significance of the mediating effect 
and to determine whether the change from path c to path c’ of the standardized regression 
coefficients was statistically significant.  The statistically significant decrease (Sobel tests 
= 2.24, p = .03) verified that perceived susceptibility partially mediated the relationship 
between perceived discrimination and interest in genetic testing. A graphic representation 
of this effect can be found in Figure 2.5 
 
Figure 2.5 Mediating role of perceived susceptibility in the relationship between 
perceived discrimination and interest in genetic testing 
 
  2.4.6 BRCA1/2 Knowledge  
 In general, women in this study scored high on all measures of knowledge of 
BRCA1/2.  For 5 of the 6 items, greater than or equal to 77% of women were able to 
correctly identify true or false statements.  However, only 53% of participants were able 
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to correctly identify the statement, “The BRCA gene causes about one half of all breast 
cancers” as “False”. 
 
2.5 Discussion 
The purpose of this study was to assess women’s interest in and attitudes towards 
genetic testing for hereditary breast cancer across multiple demographic factors.  The 
main goals of the study were to identify factors that predict women’s interest in testing 
and to clarify women’s perceptions of the utility of testing through the use of a Health 
Belief Model (HBM). Given the rapidly evolving attitudes towards and increasing 
accessibility to genetic testing, potential consumers’ thoughts regarding this service are 
especially pertinent.  
Previous studies have shown that genetic testing services are primarily utilized by 
Caucasian women with private health insurance, and higher levels of education and 
income. Minorities are less likely to be aware of the genetic testing services available to 
them (Glenn, Chawla, & Bastani, 2012). Minority women have previously cited barriers 
to testing such as accessibility, language barriers, and distrust in the medical community 
(Glenn, Chawla, & Bastani, 2012; Thompson et al., 2003). 
  2.5.1 Awareness of Genetic Testing Services  
The results of this study suggest the majority of women are aware of genetic 
testing services.  Our study noted statistically significant differences in frequency of 
awareness between multiple demographic categories.  Among our participants, black 
women, women who had lower levels of education, and women with lower annual 
incomes were all less aware of hereditary breast cancer genetic testing.  These results 
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support the findings of previous studies, and indicate that further outreach in low 
socioeconomic communities by genetics professionals may be beneficial in reducing 
disparities among consumers (Komenaka et al., 2015; Mai et al., 2014).   
  2.5.2 Interest in Genetic Testing for Hereditary Breast Cancer 
Over half of our participants expressed interest in utilizing genetic testing for 
hereditary breast cancer syndromes.  There were statistically significant differences 
between the women who reported interest and those who did not.  Some of these 
differences appear to stem from family unit demographics.  Single women were more 
likely than married women to report interest, and women with no children were more 
likely to report interest in testing than women with 2 or more children.  This observation 
adds support to previous findings suggesting women who perceive themselves to have 
stronger social supports are more likely to postpone genetic testing (Hesse-Biber & An, 
2016). 
Age had a statistically significant relationship with interest in testing.  Consistent 
with previous findings, younger women were more likely to express interest in genetic 
testing for hereditary breast cancer than older women in our sample. As patient 
populations age, they have been found to have decreased interest in medical information 
seeking (Turk-Charles, Meyerowitz, & Gatz, 1997). Alternatively, younger women’s 
increased interest in testing may be attributable to more exposure or education on genetic 
testing in their formal schooling, or an acknowledgement of the approaching midlife 
years and the increased risk of cancer that accompanies them (Sanderson et al., 2004; 
Bottorff et al., 2002).  
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Women who reported receiving lower levels of education were more likely to 
report interest in testing services than those who reported higher levels of education 
Women who have higher levels of education may have more access and knowledge 
regarding genetic technology and may be more aware of the limitations and indications 
for genetic testing than those who have received lower levels of education (Sanderson et 
al., 2004). 
Notably, no statistically significant relationship between prior awareness of 
testing services and interest in testing services was observed.  Selected populations that 
reported less awareness of services, such as black women and women with lower annual 
incomes, did not have a statistically significant difference in their reported interest when 
compared to other participants.  However, black women did trend towards significance in 
being more likely to report interest than non-Hispanic white women.   
  2.5.3 Health Belief Model 
In this study, the Health Belief Model (HBM) provided a framework to better 
understand women’s perceptions regarding the utility, benefits, barriers, and risks of 
genetic testing for hereditary breast cancer. The HBM was used to not only examine 
women’s perceptions as a whole, but also women’s perceptions within demographic 
categories in order to help clarify differing attitudes towards genetic testing for hereditary 
breast cancer. 
Overall, participants expressed a positive attitude towards genetic testing for 
hereditary breast cancer syndromes.  On average, women agreed with all of the proposed 
benefits to testing and disagreed with the majority of proposed barriers.  Women agreed 
most strongly with the proposed benefits that genetic testing would help them learn about 
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their children’s risk for breast cancer, help inform action regarding dealing with cancer 
risk, and help other family members make testing decisions.  These benefits all confer 
alterations to the personal health management of the participant and their family 
members, and indicate that women are aware of and appreciate the clinical utility of this 
testing.  
As a whole, women in this study only agreed with one proposed barrier to genetic 
testing for hereditary breast cancer syndromes. Participants were more likely to cite 
agreement with the statement that they would not be able to afford the cost of testing, 
suggesting that the perceived financial burden of genetic testing is a deterrent to women’s 
decisions to pursue testing. Current billing procedures for genetic testing for hereditary 
cancer syndromes are complex and vary based on indication, insurance plan, and the 
laboratory chosen to complete the testing. The cost of genetic testing for hereditary 
cancer billed to insurance may vary from $1,500 to $5,000, but if the patient is 
determined to be an appropriate candidate for testing, out of pocket expenses are 
anticipated to be much lower at approximately $100 (Invitae, 2017; Myriad Genetics, 
2017). Currently, many laboratories offer financial assistance programs for underinsured 
patients determined to be appropriate candidates for testing that can reduce the out of 
pocket cost to less than $100 or waive the out of pocket cost completely.(Invitae, 2017; 
Myriad Genetics, 2017). Education prior to the genetic counseling appointment regarding 
the average anticipated cost of testing may help encourage women who believe this 
service is not financially attainable to pursue genetic counseling when indicated. 
Reported interest in testing was found to be statistically significantly associated 
with women’s perceptions of their personal risk of having a genetic mutation that would 
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increase the risk of having breast cancer. Perceptions of severity were not significantly 
different between interested and uninterested women.  Stronger agreement with all of the 
proposed benefits of genetic testing was statistically significantly associated with interest, 
suggesting that women who are interested in testing are also more likely to perceive there 
to be clinical and personal utility in testing than those who are not. 
Women who did not report interest in genetic testing statistically significantly 
agreed more with three of the proposed barriers and risks.  Uninterested women were 
more likely to believe that testing would not affect their decisions regarding the 
management of cancer risk and would not provide new information about their cancer 
risk.  Both of these barriers relate to clinical utility and may indicate that women who are 
not interested in testing are less likely to perceive testing would provide personal health 
gain. The last barrier that uninterested women agreed statistically significantly more with 
was that testing would have a negative impact on their families. Given that the women in 
our sample who most frequently reported disinterest in testing were those who were 
married with more than one child, it is possible that this finding may be partially 
explained by appreciation for the significance a positive result would have on offspring. 
There were statistically significant differences in our sample regarding attitudes 
and beliefs of racial groups towards genetic testing for hereditary breast cancer.  Black 
women were statistically significantly less likely to be aware of testing services, 
indicating that they may be receiving less exposure and education on genetic testing 
services than other races. Interestingly, black women trended towards expressing 
significantly more interest in testing services than non-Hispanic white women.  These 
findings may suggest that a contributory factor towards the lower frequencies of minority 
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women utilizing genetic testing services is lack of knowledge of and access to these 
services, as opposed to a lack of appreciation of the potential utility of these services.  
Black women were statistically significantly more likely to agree with three 
barriers or risks to genetic testing than non-Hispanic white women.  Black women were 
significantly more likely to agree that they were afraid to undergo genetic testing because 
they did not understand what would be done, and that they could not afford the cost of 
testing.  Both of these barriers cite educational and accessibility concerns that may be 
aided by counseling and outreach.   
Black women were also more likely to agree with the statement that they would 
not be able to cope with the results of genetic testing. Previous studies have revealed a 
complex relationship between fear of cancer and use of screening services.  Women who 
perceive themselves to be mildly or severely at risk of cancer are less likely to utilize 
mammography than women who perceive themselves to be at moderate risk (Andersen et 
al., 2003). The underuse of mammography in black women has been hypothesized to be 
partially influenced by enhanced perceptions of breast cancer fatalism.  In a qualitative 
study, African American women described coping strategies such as denial and 
repression to deal with fear of death due to breast cancer that caused them to avoid 
preventative care, such as breast cancer screening (Peek, Sayad, & Markwardt, 2008).  
Prior studies have also noted that women who report more intense emotional 
representations of hereditary cancer and difficulty understanding hereditary cancer are 
more likely to report difficulty coping with hereditary cancer testing (Voorwinden & 
Jaspers, 2015).  It is possible a contributory factor to black women’s underuse of genetic 
testing services is related to an underlying fear of breast cancer diagnosis and an 
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enhanced perspective of the probability of death due to breast cancer. Genetic counselors 
should be aware that these patients may benefit psychosocially as they adjust emotionally 
throughout the testing process from counseling addressing the effectiveness of treatment 
for breast cancer when medical care is proactively sought. 
In our study, socioeconomic status was found to be associated with more 
agreement with perceived barriers to genetic testing. Education, health insurance 
coverage, and annual household income all statistically significantly influenced women’s 
attitudes towards genetic testing for hereditary breast cancer.  Women were more likely 
to agree that they would not be able to afford the cost of genetic testing if they had 
received less than a bachelor’s degree, if they were currently uninsured or utilizing 
university-provided health insurance, or if they reported a household income of less than 
$125,000.  The financial burden of genetic testing is a significant concern for women in 
lower socioeconomic classes that may be aided by education on patient assistance 
programs and financial aid counseling. Women who reported receiving less than a 
bachelor degree, government-provided insurance, and a household income of less than 
$10,000 were all more likely to agree that they were afraid to undergo genetic testing 
because they did not understand what would be done. Education in low socioeconomic 
communities should include an exploration of the agenda of a genetic counseling session 
and the subsequent testing process. 
  2.5.4 Discrimination 
Previous studies consistently note the significance of historical discrimination and 
residual distrust in the medical community as a barrier to genetic testing in minority 
women (Kennedy, Mathis, & Woods, 2007; Glenn, Chawla, & Bastani, 2012). The 
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participants in our study did not statistically significantly differ in their reports of 
discrimination between racial groups or socioeconomic factors.  Our results indicated a 
statistically significant relationship between reported interest in testing and increased 
frequency of daily events of discrimination.  Further analysis revealed a confounding 
relationship between interest and discrimination that was partially explained by 
perceptions of susceptibility to a cancer predisposing mutation.  Women who reported 
higher perceptions of susceptibility to a mutation not only significantly scored higher on 
the daily discrimination scale, but also reported significantly more interest in testing.  
This relationship indicates that women who experience more discrimination may perceive 
themselves to be more susceptible to a mutation that would increase their risk of breast 
cancer.   
Previous studies have linked discrimination to many adverse physical and mental 
health outcomes (Pascoe & Richman, 2009). To our knowledge, this is the first study to 
show a relationship between discrimination and increased perceptions of susceptibility to 
a genetic syndrome.  Discrimination has the potential to be a source of chronic stress that 
may accumulate to have significant effects on long-term health. Beyond the impact stress 
may have on health, distress and anxiety have been associated with overestimations of 
cancer risk (Tilburt, et al., 2011). Our findings indicate that those who experience 
discrimination may be at greater risk of anxiety inflating their perceptions of their risk of 
having a genetic mutation that would cause an increased risk of cancer. 
  2.5.5 BRCA1/2 Knowledge  
Overall, the women in our sample scored high on the knowledge portion of the 
questionnaire.  Of note, one item, “The BRCA gene causes about one half of all breast 
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cancers” (False), was answered incorrectly by almost half of the sample. As BRCA 
mutations account for approximately 5% of all breast cancer cases, women in this study 
had inflated perceptions of the frequency of BRCA related cancers. Women may benefit 
from education and counseling from their healthcare providers regarding the frequency of 
genetic cancers. 
  2.5.6 Practice Implications 
Previous studies have noted the underuse of preventative genetic testing for 
hereditary breast cancer in minority women.  This study revealed that black women tend 
to be less aware of genetic testing services, but equally as interested as their peers in 
receiving them, indicating that lack of knowledge and accessibility are key contributory 
factors to this underutilization as opposed to a lack of appreciation of the potential utility 
of genetic testing for hereditary breast cancer.  Similarly, women of lower socioeconomic 
status, who reported lower household incomes, levels of education, and government 
provided health insurance, were more likely to be unaware of services than their peers but 
no less interested. Increasing exposure to genetic testing services in underserved 
populations is possible, but may require the aid of multiple health care providers. 
Mobile mammography has been shown to be an effective method at increasing 
breast cancer screening in underserved communities and offering a channel of access to 
women who have barriers to the medical community (Chen et al., 2016; Brooks et al., 
2013; Massin-Short et al., 2010). Given that our participants from these communities 
expressed equal interest in genetic testing, despite less awareness, our findings support 
the inclusion of a genetic counselor or genetics-trained health provider on a mobile 
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mammography unit to speak with interested or high-risk women as a strategy to allow for 
more education and exposure to genetic testing in these populations. 
A novel relationship between increased experiences of discrimination and 
increased perceptions of susceptibility to a genetic mutation that would increase breast 
cancer risk was noted in our participants.  Prior studies have indicated that women who 
feel more discrimination are less likely to utilize health services (Pascoe & Richman, 
2009; Andersen et al., 2003). While it may be more difficult to reach women who feel 
more discrimination, they may benefit significantly from counseling and education 
regarding risk estimates and strategies to decrease the risk of cancer.  
As stated previously, historically, minorities, women who have non-private health 
insurance, and women in lower socioeconomic classes are among the least likely to 
pursue genetic testing services.  In our study, black women, women with government-
provided health insurance, women with lower annual household incomes, and women 
with less formal education all consistently agreed statistically significantly more with one 
barrier to testing, “I am afraid to undergo genetic testing because I do not understand 
what will be done”. Unlike many of the potential barriers proposed in this study, this is a 
patient concern genetic counselors and other health professionals are equipped to directly 
address and impact.  
Genetic counselors providing cancer-based genetic testing services should be 
aware that minority women and women with lower socioeconomic status may arrive to a 
genetics appointment with different concerns than other patients.  Beyond contracting 
with the patient, specifically addressing the procedural and logistical aspects of the 
genetic testing process early in the appointment may aide in reducing perceived barriers 
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to these patients. Although unconventional, touching on the testing process and 
anticipated cost of testing prior to or in the beginning of the appointment may allow 
women less comfortable in a medical setting to better focus on the genetic information 
and education portions of the session later on if their concerns are adequately addressed 
from the start. Additionally, information and educational materials designed for women 
in underserved communities should specifically address the procedural and financial 
aspects of genetic testing. 
 
2.6 Limitations and Future Studies  
 One of the goals of this study was to capture the perspectives of a diverse 
population. In order to do so, a number of self-selecting sampling methods were utilized, 
which created potential self-selection bias. Women who chose to participate in this study 
may have had stronger beliefs and attitudes towards genetic testing than women who did 
not.  
While the sample collected was diverse in terms of education, income, age, and 
family unit characteristics, 85% of participants reported residing in the eastern region of 
the United States.  Future studies may wish to explore differences in attitudes across the 
United States. Black women were well represented in the study, but the perspectives of 
women of other minority groups were less represented.  These results are not 
generalizable to women of all minority backgrounds. 
 Information regarding HBOC and genetic testing was provided in a summary to 
the participants. It is not clear if participants fully understood the summery, as the item 
used to assess knowledge of BRCA1/2 most frequently incorrectly answered by 
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participants was addressed in the summery.  This may exemplify the complex nature of 
explaining genetic predispositions by written material alone.  We did not determine how 
participants received information regarding genetic testing and HBOC. Learning which 
sources women use to learn about genetic testing and hereditary cancer risk may have 
provided revealing information. 
While the HBM provided an abstract framework for exploring women’s 
perceptions and attitudes towards genetic testing, further clarification through qualitative 
data would have aided in the interpretation of results. A significant observation that was 
noted in this study was women’s agreement that the cost of testing was perceived as a 
barrier. Participants were not asked specifically what they believed the cost of testing to 
be.  Future studies should explore women’s concrete perceptions of the potential financial 
burden of genetic testing to form a more accurate picture of this significant barrier. 
 This study focused specifically on the breast cancer risks of HBOC. In reality, 
women with BRCA1/2 mutations are at increased risk for multiple cancers, including 
ovarian and pancreatic cancer.  It is possible that knowledge of these cancers risks may 
have an impact on participants’ interest in and attitudes towards genetic testing for 
BRCA1/2 that was not measured in this study. 
 A relationship between women’s reports of discrimination, increased interest in 
testing, and increased perceptions of susceptibility to the inheritance of a genetic 
mutation that would increase breast cancer risk was noted.  To our knowledge, this is the 
first study to demonstrate this relationship.  It would be interesting to explore if this 
relationship is present in other adult-onset conditions that are moderated by both genetic 
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risk and environmental risk factors like stress and anxiety, such as Alzheimer’s disease or 
heart disease.   
 The results of this study support intervention and outreach, potentially through 
mobile mammography or mobile health units, in underserved communities to provide 
education on genetic testing. Future studies should examine the effectiveness of such 
interventions in the appropriate utilization of genetic testing services in underserved 
communities, as well as the effectiveness of altering the genetic counseling agenda to 
address issues such as expected out of pocket costs and the testing procedure prior to the 
genetic counseling session through handout or phone call, or in the beginning of the 
genetic counseling session.  
 
2.7 Summary 
 In recent years, genetic testing for hereditary cancer syndromes has not only 
become more accessible to the general population, but also received more media attention 
and exposure, increasing the general public’s awareness of this medical service.  Genetic 
testing offers many potential benefits, including earlier and more frequent screening to 
prevent advanced stages of cancer, and the provision of personalized risk information to 
family members.  Given the rapidly evolving attitudes towards and increasing 
accessibility to genetic testing, potential consumers’ thoughts regarding this service are 
especially pertinent.  
 Our findings indicate that the majority of women are aware of and interested in 
genetic testing for hereditary breast cancer syndromes, and perceive there to be clinical 
and personal utility in testing, across demographic categories.  
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We noted statistically significant differences in the concerns and barriers to 
genetic testing cited by black women and women of lower socioeconomic status when 
compared to other participants.  We suggest that genetic counselors providing services to 
these women are especially cognizant of the potential concerns of cost and lack of 
awareness of what genetic testing entails expressed by these populations, and consider 
addressing these concerns prior to or earlier in the genetic counseling session to ensure 
these patients are able to focus on the education provided without the distraction of these 
potential barriers.  Future studies are necessary to determine the effectiveness of this 
proposal.  
We observed  a relationship between participants reports of increased frequency 
of discrimination and increased interest in genetic testing that was partially modified by 
participant’s perceptions of their susceptibility of having a genetic mutation that would 
increase their risk of cancer.  These results suggest that women who experience more 
discrimination have inflated perceptions of their hereditary cancer risk.  Future studies 
may wish to explore if this relationship is present with other adult-onset diseases with 
genetic risk, such as heart disease or Alzheimer’s disease. Previous studies have shown 
that individuals who experience more discrimination are less likely to utilize medical 
services. Given that the women in our study who reported more discrimination cited 
higher concern about their susceptibility to a mutation as well as increased interest in 
testing, strategic outreach to provide counseling services on personalized risk estimates to 
this population may aide in decreasing cancer-related anxiety.  
Our findings have shown that women from underserved communities and women 
who experience more discrimination are equally as interested in genetic testing as other 
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participants, but more likely to experience barriers related to education and access that 
make obtaining services more difficult.  We recommend the inclusion of a genetics 
trained health professional on health units designed to reach underserved communities to 
aide in counseling on hereditary cancer risk and the process of obtaining genetic testing 
to women who qualify as high-risk. Future studies are necessary to determine the 
effectiveness of this proposed intervention in increasing the uptake of appropriate testing 
in these populations. 
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CHAPTER III. CONCLUSIONS 
 In this study, participants were generally aware of and interested in genetic testing 
services. We accept our hypothesis that participants of all backgrounds express similar 
levels of interest in genetic testing services.  While women from traditionally 
underserved populations were less likely to have heard of genetic testing for hereditary 
breast cancer prior to this study, they reported similar levels of interest to other 
participants in this study. 
Notably, there were no significant differences between populations’ agreement 
with benefits and barriers regarding the clinical utility of testing, suggesting that even 
women who have less exposure to genetic technology are able to perceive the benefit and 
personal gain they might receive through predictive risk analysis. 
 As we expected, women from traditionally underserved populations were more 
likely to agree with proposed barriers regarding accessibility. Specifically, women from 
these populations agreed significantly more that they were concerned about cost and lack 
of awareness of what would be done in genetic testing. 
 We observed an unanticipated relationship between perceived susceptibility to a 
risk increasing genetic mutation and experiences of discrimination.  Women who 
experience more discrimination may also have increased levels of stress and anxiety that 
inflate perceptions of hereditary cancer risk.  
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APPENDIX A. PARTICIPANT RESOURCES 
LOCATE A GENETIC COUNSELOR 
If at any point during this questionnaire you became concerned about your risk of having 
a genetic mutation that would increase your chance of having cancer, consider contacting 
a local genetic counselor by following the steps below: 
1. Go to the National Society of Genetic Counselors website homepage at: 
http://www.nsgc.org/ 
2. On the NSGC homepage, click the link titled, “Find a Genetic Counselor” in the 
bottom right hand of the corner of your screen 
 
3. Enter your postal code and make sure to click “Cancer” under specialization. 
Then, click search!  
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APPENDIX B. INVITATION TO PARTICIPANTS 
University of South Carolina School of Medicine 
USC Genetic Counseling Program 
 	
Dear Potential Participant,  
 
You are invited to participate in a graduate research study focused on women’s 
perceptions of the purpose of genetic testing for hereditary breast cancer syndromes.  I 
am a graduate student in the genetic counseling program at the University of South 
Carolina School of Medicine. My research investigates factors that influence women's 
interest in genetic testing. This research will involve the completion of this questionnaire, 
which will collect information about you and your viewpoints regarding genetic testing 
and cancer. Your responses will help genetic counselors and health providers better 
understand women's viewpoints regarding genetic testing services and provide these 
services to a broader range of women. 
 
All responses gathered from the surveys will be kept anonymous and confidential. The 
results of this study might be published or presented at academic meetings; however, 
participants will not be identified.  
 
Your participation in this research is voluntary. By completing the questionnaire, you are 
consenting that you have read and understand this information. At any time, you may 
withdraw from this study by not completing the questionnaire. 
 
 If you have any questions regarding this research, you may contact either myself or my 
faculty advisor, Crystal Hill-Chapman, Ph.D., using the contact information below. 
 
 
Taylor Apostolico, BS       Crystal-Hill Chapman, PhD 
(610) 955 9615                 (843) 661 1721 
taylor.apostolico@gmail.com       chillchapman@fmarion.edu 
 
If you have any questions about your rights as a research participant, you may contact the 
Office of Research Compliance at the University of South Carolina at (803) 777-7095. 
 
Thank you for your time and consideration to participate in this survey! 
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APPENDIX C. LETTER OF SUPPORT 
University of South Carolina School of Medicine 
USC Genetic Counseling Program 		
To the University of South Carolina IRB: 
 
I am familiar with Taylor Apostolico’s research project entitled “Assessing Women’s 
Attitudes Towards Genetic Testing for Hereditary Breast Cancer”.  I understand 
[Organization Name] involvement to be permitting interested clients and community 
members to be surveyed and distributing questionnaires. 
 
I understand that this research will be carried out following sound ethical principles and 
that participant involvement in this research study is strictly voluntary and provides 
confidentiality of research data, as described in the protocol. 
 
Therefore, as a representative of [Organization Name] I agree that Taylor Apostolico’s 
research project may be conducted at our agency. 
 
 
Sincerely, 
 
 
_______________________________   ______________________ 
Organization Representative        Date 
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APPENDIX D. BACKGROUND INFORMATION 
	 	 HEREDITARY 
BREAST CANCER 
A Brief Introduction	
	
What is Hereditary Breast Cancer? 
 
Breast cancer is a cancer that develops from the breast tissue. It affects 1 in 8 women in 
the United States. Typically, this happens by chance. In a small percentage of breast 
cancer cases, it is caused by a genetic mutation in one of a few genes. When one of these 
genes has a mutation, it stops working leading to an increased risk of cancer.  This form 
of breast cancer is called hereditary breast cancer. 
 
Two of the more common genes that cause hereditary breast cancer are the BRCA1 and 
BRCA2 genes.  Women who have mutations in these genes have a higher risk of 
developing a few cancers, including breast and ovarian cancer.  Around 1-3% of people 
in the United States have a mutation in one of these genes. It is possible to test a person’s 
blood for the presence of mutations that may cause a person to have an increased chance 
of getting breast cancer. For the purpose of this study, this process of obtaining genetic 
information related to a person’s risk of having breast cancer will be called ‘genetic 
testing for hereditary breast cancer’ 
 
What is a Genetic Counselor? 
 
Genetic counselors are trained health care workers that help individuals understand the 
many implications of genetic contributions to disease.  Genetic counselors use family and 
personal histories to determine an individuals’ risk of having a genetic mutation, like one 
in a BRCA gene, that would increase the individual's risk of having cancer. 
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APPENDIX E. QUESTIONNAIRE 
 
1. Had you heard of genetic testing for hereditary breast cancer before beginning this 
survey?       
 Yes    No 
 
2. Have you personally had genetic testing for hereditary breast cancer before?  
 
 Yes   No 
 
3. Is genetic testing for hereditary breast cancer something you would be interested in 
pursuing?  
 
Yes   No 
 
4. What do you think your chance is of developing breast cancer in your lifetime? Please 
choose a number between 0 (no chance of breast cancer) and 100 (definitely will get 
breast cancer) 
 
 
5. How strongly do you agree or disagree with the following statements?  
 
It is likely that I carry a gene mutation that increases my risk for breast cancer 
 Strongly Disagree  Disagree   Agree   Strongly Agree 
 
The chances that a gene mutation runs in my family are great 
 Strongly Disagree  Disagree   Agree   Strongly Agree 
 
 
6. How strongly do you agree or disagree with the following statements?  
 
If I found out that I carried a gene mutation, it would greatly disrupt my life 
 Strongly Disagree  Disagree   Agree   Strongly Agree 
 
Finding out I carried a gene mutation would be very difficult for me 
 Strongly Disagree  Disagree   Agree   Strongly Agree 
 
If I found out I carried a gene mutation, I would worry much more about developing breast 
cancer 
 Strongly Disagree  Disagree   Agree   Strongly Agree 
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7. How strongly do you agree or disagree with the following statements?  
 
I am afraid to undergo genetic testing because I may not be able to cope with the result 
 Strongly Disagree  Disagree   Agree   Strongly Agree 
 
Genetic testing will not tell me anything about my risk I do not already know 
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
Genetic testing to learn about my risk will give me a sense of personal control  
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
Genetic testing will lead to unfair treatment of some people – that is, discrimination 
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
Genetic testing will help me reduce uncertainty about the future 
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
Genetic testing will help me decide on the best course of action to take to deal with my 
cancer risk  
 Strongly Disagree  Disagree   Agree   Strongly Agree 
 
My family will not be supportive if I undergo genetic testing 
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
Genetic testing will help me learn about my children’s risk for breast cancer 
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
I cannot afford the cost for genetic testing 
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
Genetic testing will ease my mind, regardless of the test result  
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
I am afraid to undergo genetic testing because I do not understand what will be done 
  Strongly Disagree  Disagree   Agree   Strongly Agree 
  
Genetic testing to learn my risk will help other family members decide whether to undergo 
testing 
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
Genetic testing will not help me because I would not do anything different to manage my 
cancer risk  
  Strongly Disagree  Disagree   Agree   Strongly Agree 
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Genetic testing will have a negative impact on my family  
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
Genetic testing will help me make important life decisions (such as getting married, having 
children) 
 Strongly Disagree  Disagree   Agree   Strongly Agree 
 
 
8. How strongly do you agree or disagree with the following statements?  
 
I can solve most problems if I invest the necessary effort 
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
I am confident that I could deal efficiently with unexpected events 
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
If I am in trouble, I can usually think of a solution 
  Strongly Disagree  Disagree  Agree   Strongly Agree 
 
If someone opposes me, I can find the means and ways to get what I want 
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
When I am confronted with a problem, I can usually find several solutions 
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
It is easy for me to stick to my aims and accomplish my goals 
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
I can usually handle whatever comes my way 
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
I can always manage to solve difficult problems if I try hard enough  
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
Thanks to my resourcefulness, I know how to handle unforeseen situations  
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
I can remain calm when facing difficulties because I can rely on my coping abilities  
  Strongly Disagree  Disagree   Agree   Strongly Agree 
 
 
9. In your day-to-day life, how often do the following things happen to you?  
 
You are treated with less courtesy or respect 
 Never   Rarely   Occasionally   Frequently 
 
You receive poorer service than other people 
 Never   Rarely   Occasionally   Frequently 
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People act as if they think you are not smart  
 Never   Rarely   Occasionally   Frequently 
 
People act as if they are afraid of you  
 Never   Rarely   Occasionally   Frequently 
 
You are threatened or harassed  
 Never   Rarely   Occasionally   Frequently 
 
 
10. Please answer the following questions as either True or False 
 
A father can pass down an altered BRCA gene to his daughters 
  True   False 
 
All women who have an altered BRCA gene will get cancer 
  True   False 
 
A woman who has a sister with an altered BRCA gene has a 50% chance of having an altered 
BRCA gene herself 
  True   False 
 
A woman who doesn’t have an altered BRCA gene can still get cancer 
  True   False 
 
There are many different genes that cause cancer 
  True   False 
 
The BRCA gene causes about one half of all breast cancers 
  True   False 
 
 
11a. Have you ever been diagnosed with cancer?  
 Yes    No 
 
11b. If so, what type of cancer were you diagnosed with?  
 
 
11c. If so, at what age(s) were you diagnosed with cancer?  
 
 
12a. Have you ever had genetic testing for any condition?  
 Yes    No 
 
12b. If so, what was the reason you had genetic testing?  
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13a. Has anyone in your family been diagnosed with breast cancer at any time in their 
life?  
 Yes    No 
 
13b. If so, how many relatives have had breast cancer?  
 
13c. If so, which relative(s) have had breast cancer? Please check all that apply.  
 Mother      Aunt (on mother’s side) 
 Sister      Aunt (on father’s side) 
 Daughter      Cousin (on mother’s side) 
 Grandmother (on mother’s side)   Cousin (on father’s side) 
 Grandmother (on father’s side)   Other (please specify)_____________ 
 
14. Does your family have Ashkenazi Jewish ancestry?  
 Yes   No 
 
15. What race do you most identify with?  
  Alaskan Native     Native Hawaiian  
  American Indian     Non-Hispanic White 
  Asian      Pacific Islander 
  Black American     Other (please specify)_________________ 
  Hispanic 
 
16. What is the highest level of school you have completed or the highest degree you 
have received?  
  Less than high school degree  
  High school degree or equivalent (e.g., GED) 
  Some college but no degree  
  Associate degree 
  Bachelor degree 
  Graduate degree 
 
17. What type of health insurance are your currently covered by?  
 Currently uninsured  
  Student Health Insurance (provided by University) 
  Medicare  
  Medicaid 
  Employer provided private insurance 
  Self-provided private insurance 
 
18. Which of the following best describes your current relationship status?  
 Married  
  Widowed 
  Divorced 
  Separated 
  In a domestic partnership or civil union 
  Single, but cohabiting with a significant other 
 Single, never married 
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19. How much total combined money did all members of your household earn last 
year?  
  $0 to $9,999     $125,000 to $149,999 
  $10,000 to $24,000    $150,000 to $174,999 
  $25,000 to $49,999    $175,000 to $199,999 
  $50,000 to $74,999    $200,000 and up 
  $75,000 to $99,999    Prefer not to answer 
  $100,000 to $124,999 
20. What is your zip code? __________________ 
 
21. How many children do you have? _________ 
22. What is your current age? _________ 
